NUTM2A and gastric cancer: In gastric cancer, NUTM2A-AS1 sponges miR-376a, which normally suppresses TET1 and HIF-1A; the resulting increase in these proteins subsequently elevates PD-L1 expression, thereby promoting cell viability, invasion, and chemoresistance [51].